Scouting for early-stage oncology opportunities
Challenge
A listed North American company needed support with the identification, assessment and in-licensing of early-stage oncology assets.
Solution
We consulted our industry network and contacts and identified a number of high-quality opportunities that had not yet been analyzed by our client’s in-house business development team.
We’re working closely with our client’s scientific staff to screen and assess opportunities before entering heads of terms. We’re also giving advice on structuring heads of terms, due diligence and license negotiations.
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Scouting for assets discontinued from development due to neutralizing antibodies (Nabs)
Challenge: An early-stage biotech company asked Alacrita to identify drug program assets that had been discontinued from further development due to neutralizing antibodies (Nabs)...
Asset scouting for novel injectable formulations for large pharma
Challenge: A public, multi-national pharmaceutical company historically focused on producing generics (including branded), active pharmaceuticals ingredients, biologics, and over...
Pre-Due Diligence Assessment of First-in-Class Allergy Therapeutic
Challenge: A pharmaceutical company seeking new assets requested a pre-due diligence assessment of a European biotech developing a first-in-class compound for treating allergic...
Strategic Partnership Assessment of Autoimmune Drug Development Program
Challenge: A pharmaceutical client asked Alacrita to assess a early-stage biotech company developing an orally-available agent for treating various autoimmune conditions. The...
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.